Nemocnice Jihlava prispevkova organizace — Clinical Trial Site

39 Registered trials

12 Currently recruiting

Organisation

Nemocnice Jihlava prispevkova organizace

Location

Jihlava 1, Czechia

Identifier

ORG-100020545

Address

Vrchlickeho 4630/59, 586 01, Czechia

Departments

#2053: Neurologicke oddeleni
#7210: Neurologická klinika
2022: Neurologické oddělení
203005: Neurologicke oddeleni
2319: Kardiologické oddělení
2544: Kozni oddeleni
7510: Kardiologicke oddeleni
Cardiology
Kardiologicke oddeleni
Nemocnice Jihlava - Kardiologické oddělení
Neurologicke oddeleni
Neurologie - MS centrum
Neurologie - RS centrum
Neurology
PED – Pediatrické oddělení
Pediatricke oddeleni
Plicní oddělení
Pneumology

Clinical trials at this site (39)

Search interface

A Study Providing Continued Access to Treatment in Patients with a Neurological Disease Previously Enrolled in a Genentech and/or F. Hoffman… Not authorised

2023-507633-21-00 Neurological Disease 5
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRES… Recruiting

2025-522170-36-00 Diabetes Mellitus, Type 1 5 2026-02-03
A Phase 2 Study of Obexelimab in Patients with Relapsing Multiple Sclerosis Recruiting

2024-512707-40-00 RELAPSING MULTIPLE SCLEROSIS 4 2024-11-07
Efficacy and safety study of frexalimab (SAR441344) in adults with relapsing forms of multiple sclerosis Recruiting

2023-504358-36-00 multiple sclerosis 5 2024-10-17
EFFICACY AND SAFETY OF MET097 ONCE WEEKLY IN PEOPLE WITH OVERWEIGHT OR OBESITY AND TYPE 2 DIABETES (VESPER-5) Recruiting

2025-523975-48-00 Obesity 5 2026-05-08
Efficacy And Safety of MET097 Once Weekly In People With Overweight or Obesity (VESPER-4) Recruiting

2025-523974-18-00 Obesity 5 2026-04-30
HF-POLARIS: A research study to look at how well NNC0487-0111 works compared to placebo in people with heart failure and obesity Recruiting

2025-523717-29-00 HFpEF or HFmrEF and obesity 5 2026-04-28
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosi… Recruiting

2025-521546-23-00 Secondary progressive multiple sclerosis 5 2026-04-21
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and … Recruiting

2024-516652-18-00 Atherosclerotic cardiovascular disease (ASCVD) and obes 5 2025-10-10
Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o… Recruiting

2023-509275-17-00 Relapsing multiple sclerosis 5 2025-10-06
A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting

2023-503631-18-01 Nervous system diseases 5 2024-05-20
Frexalimab in preservation of endogenous insulin secretion compared to placebo in adults, adolescents and children on top of Insulin therapy… Recruiting

2022-500531-36-00 Type 1 diabetes mellitus 4 2024-02-02
Extension study to assess effects of non-interrupted versus interrupted and long term treatment of two dose regimens on efficacy and safety … Recruiting

2023-508956-20-00 Hidradenitis suppurativa 5 2020-03-12
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici… Ended

2025-521127-73-00 Relapsing forms of Multiple Sclerosis 5 2025-09-12
Efficacy and safety study of frexalimab (SAR441344) in adults with nonrelapsing secondary progressive multiple sclerosis Ended

2023-504359-29-01 Multiple sclerosis 5 2024-12-11
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended

2023-504827-17-00 Chronic migraine 5 2024-03-18
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended

2023-504839-40-00 Episodic Migraine 5 2024-03-18
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidit… Ended

2023-504413-80-00 Obesity 5 2023-12-07
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
OCEAN(a)-Outcomes – Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction – Outcomes trial Ended

2022-501608-85-00 Cardiovascular disease (atherosclerotic cardiovascular 5 2023-05-09